Lupin Limited

Overall Rating: star ratingstar ratingstar ratingstar ratingstar rating[0/5]Total Votes [  ]  
Rate this page:
Lupin Limited - About the Company

Lupin Limited is an intercontinental firm involved in the creation and advancement of APIs, standard and branded medicines. It is one of the biggest producers of Tuberculosis medicines worldwide and has an onshore as well as offshore existence of its manufactured goods in more than 65 nations. Its production center is situated in Japan and among the Indian states of Ankleshwar, Aurangabad, Mandideep, Goa, Jammu, Indore and Ankleshwar.

The production units of the firm are authorized by several global authoritative agencies like UK MHRA, WHO, US FDA, MCC South Africa and TGA Australia. In formulation segment it provides an extensive range of goods for the cure of Asthma, Diabetology, Cephalosporins, GI, CVS, Anti-TB, CNS, etc. These products entail 70% of the firm’s business. It has a dominant market existence in Australia, USA, Japan and Europe, and in expanding markets and international nations.

In APIs division the firm has a range of product contributions for healing of Tuberculosis, Cephalosporins, Cardiovasculars, etc. Lupin has procured Novodigm in Contract Research and Manufacturing Services (CRAMS) segment. Novodigm is engaged in expanding and authorizing goods.

Lupin Limited has been felicitated with "Best New Manufacturer of the Year, Generics Rx", by one of the biggest traders in the US, Amerisource Bergen. Besides, the firm has also been honored with two major awards by Cardinal Health namely "Quality Supplier Award" and "Trade Representative of the Year". In the year 2003, the firm bagged the prestigious Business world FICCI-SEDF Corporate Social Responsibility Award.

The firm has attained marginal stake in Generic Health Pty, an Australian governed and controlled standard pharma firm that has an extensive range of quality standard drugs instruction and OTC goods.

Lupin Limited - Products

Lupin Limited has selected quality, competence and value control as the foundation of its APIs (Active Pharmaceuticals Ingredients) trade. Besides APIs, the firm also produces and sells superior API penultimates. It has an incorporated Ayurveda and improved skills of contemporary science to produce an efficient collection of herbal medicines in the restorative segments of GI, gynecology, Pediatrics, gastro intestinal, and diabetes.

The research and development activities of Lupin concentrate on three segments such as:

  • Employing artificial and therapeutic methods for New Chemical Entities (NCE)
  • Use of Generics DMFs (Drug Master Files) for APIs and ANDAs (Abbreviated New Drug Applications) for manufactured goods.
  • For the use of New Drug Delivery Systems (NDDS)


  • Products are available for:

  • Anti-viral
  • Anti-malarial
  • Iron preparations
  • Anxiolytic
  • Gastro-intestinal
  • Anti-bacterial/fungal creams
  • Quinolones
  • Anti-oxidants
  • Anti-asthma
  • Laxatives
  • Multi-vitamins
  • Herbal
  • Anti-allergy
  • Cephalosporin
  • Anti-diabetic
  • Cardiovascular
  • NSAID
  • Anti-TB


  • Lupin Limited - Financials

    The financial year 2008-09 witnessed a notable progress of around 32% in returns and 50% in earnings. In the past few years, the firm has registered a CAGR of 32% and 54% in net sales and incomes respectively. The medicines of the firm are exported to over 70 international nations.

    At present Lupin holds the exclusive feature of being the rapidly expanding top standard drugs manufacturers in the world. It was also identified as the fastest growing top 5 pharma firms in India and South Africa.

    The firm closed with returns amounting to ` 39,145 Mn in FY 2008-09 as against ` 29,583 Mn in 2007-08. The combined net profit for 2008-09 increased by 22% to ` 5,015 Mn, as against ` 4,082 Mn in 2007-08. The combined topline registered expansion was recorded at 38%. The firm’s Formulations venture at present is worth over 81% that can be translated as the steep rise from42% over the last 4 years.

    Lupin Limited - Contact Details
    Registered Office
    Lupin Ltd
    159 CST Road
    Kalina, Santacruz (E)
    Mumbai 400 098
    India
    Phone: +91 22 6640 2323
    Fax: +91 22 6640 2051
    Email: [email protected]

    Corporate Office
    Lupin Ltd
    B/4 Laxmi Towers
    Bandra Kurla Complex
    Bandra (E)
    Mumbai 400 051
    India
    Phone: +91 22 6640 2222
    Fax: +91 22 6640 2130

    E-mails for further inquiries:
    For Corporate Communications: [email protected]
    For Investor Assistance: [email protected]
    For R & D activities: [email protected]
    For Human Resources: [email protected]
    For Secretarial Assistance: [email protected]


    Last updated on 6thJuly 2011